Coronary Artery Disease Screening in Patients With Chronic Kidney Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Chronic Kidney Disease (CKD), Coronary Artery Disease (CAD). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Screening for Coronary Artery Disease in Patients With Chronic Kidney Disease
Overview
Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.
Primary outcome measures
- To assess the prognostic value of impaired coronary flow reserve measured by CZT myocardial perfusion imaging [Time frame: 2-year follow-up]
Secondary outcome measures (5)
- To assess the prognostic value of coronary flow reserve to each individual component of the primary endpoint [Time frame: 2 years]
- To assess the prognostic value of coronary flow reserve for Major Adverse Kidney Events (MAKE) [Time frame: At 1-year and 2-year follow-up]
- To assess the number of Acute Kidney Injury (AKI) events during follow-up [Time frame: 2 years]
- To assess the number of coronary revascularizations by coronary artery bypass grafting or percutaneous coronary intervention [Time frame: 2 years]
- To assess the prevalence of ischemic heart disease without significant coronary artery stenosis (INOCA) [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- Male or female patients aged over 18 years
- Affiliated with the French social security system
- Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR < 30 mL/min/1.73 m², or GFR < 45 mL/min/1.73 m² with albuminuria > 30 mg/g, or GFR < 60 mL/min/1.73 m² with albuminuria > 300 mg/g)
- Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment
- Having expressed no objection to participation in this study
Exclusion criteria
- Legally protected adult (Article L1121-8 of the French Public Health Code)
- Person deprived of liberty (Article L1121-8 of the French Public Health Code)
- Pregnant woman
- Patient who has undergone a normal coronary exploration within the past year
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- CHU Grenoble Alpes — La Tronche
Identifiers
NCT: NCT07585695 · 38RC25.0302 · IDRCB 2025-A02537-42 · 38RC25.0302